Featured Articles

  1. Annovis Bio: Against The Grain In Alzheimer's Disease 10/1/2024

    From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape. 

  2. New Leadership At The Cancer Research Institute 9/27/2024

    Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.

  3. A Supply-Chain Woman Of Iran 9/23/2024

    Arezou Mehrabi has a spellbinding supply-chain case study. It transpired, of all places, in Iran. It includes major challenges in outsourcing manufacturing to a partner CDMO for a top-ten pharma (Sanofi, to be exact). Our protagonist is a woman who took leadership within a male-dominated workplace, country, and entire region. 

  4. Where Are They Now? Carisma Therapeutics 9/22/2024

    In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.

  5. Thriving On Ambiguity: What I've Learned Leading Rare Disease Teams 9/19/2024

    Melissa Leichter, a Novo Nordisk executive, describes the distinct skills and mindset needed to succeed in bringing rare disease treatments to market.

  6. Know Your Customer: Strategic Considerations for AI-Powered Provider Segmentation 9/16/2024

    Effective provider segmentation can make or break a new drug launch, and can also improve the lifecycle of existing portfolio products. Executives at Charles River Associates offer examples of how A.I. can be used to get closer to provider customers.

  7. Improving The Clinical Trial Ecosystem: A Call To Stakeholder Alignment 9/9/2024

    Biopharmaceutical companies must address the frictions and challenges that have quietly infiltrated the drug development ecosystem and root them out, planting instead a new spirit of partnership and collaboration.

  8. 'Explainambiguity:' When What You Think Is Not What You Get 9/6/2024

    As AI integration increases across biopharmaceutical R&D functions, understanding model ambiguities with respect to AI explainability becomes increasingly important.

  9. AI Is A Tool — Not A Replacement — For Human Innovation In Drug Discovery 9/4/2024

    This attorney provides practical advice. Can artificial intelligence (AI) make drug discovery easier? Yes! Will we lose the human component essential to the innovation culture? No.

  10. A Systems Approach To Parkinson's Disease 8/30/2024

    New research into Parkinson's disease is strengthening the connection between an unhealthy gut and brain disorders.